Figure 3
From: Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen?
Proportion of oestrogen-receptor-positive women who will develop recurrence in the first 10 years of follow up for four different treatment strategies using the ‘deep model’ and a 5 year carryover effect, assuming 20% of the patients are initially ER+/PgR−: aromatase inhibitor for 5 years; 2 years of tamoxifen followed by 3 years of an AI; 5 years of tamoxifen followed by 5 years of an AI; and 5 years of tamoxifen alone. See text for parameter estimates.
